Apalutamide not checked

Janssen Research & Development, LLC · JNJ 56021927 · ARN-509

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 3 trial completes
Trials
26 active
38 in total · 22 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“240 mg tablets administered by mouth on a continuous once daily dosing regimen”In the company’s words, NCT01946204 on ClinicalTrials.gov
Tested for
Prostatic Neoplasms (8 trials), Prostate Cancer, Metastatic Castrate-sensitive Prostate Cancer, Salivary Gland Neoplasms, Metastatic Castration-Resistant Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Neoplasms and 1 more
Main trialPhase 3
“The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.”In the company’s words, NCT01946204 on ClinicalTrials.gov
Other names
JNJ 56021927 · ARN-509 · JNJ-56021927 and ARN-509

Other drugs for Prostatic Neoplasms

All 195 drugs for Prostatic Neoplasms

Coming up6

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials38

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 19 May 2017 A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Phase 3Active, not recruiting 19 Mar 2018 An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 3Active, not recruiting 7 Sep 2020 A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Phase 3Active, not recruiting 12 Oct 2026 A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
Phase 3Active, not recruiting 1 Dec 2026 A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Phase 3Active, not recruiting 1 Mar 2027 An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Phase 3Active, not recruiting 27 Aug 2029 A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Phase 2Active, not recruiting 9 Jun 2021 A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
Phase 1Active, not recruiting 27 Jun 2016 A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 1Active, not recruiting 7 Nov 2016 A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
Phase 1Active, not recruiting 9 Jul 2019 A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 1Active, not recruiting 31 Dec 2026 ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
Phase 1Recruiting 21 Jun 2027 A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Phase 1Recruiting 31 Aug 2027 A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Phase 4Completed 1 Jun 2023 A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Phase 2Completed 23 Oct 2023 A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Phase 1/2Completed 20 Aug 2012 Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Phase 1Completed 10 May 2014 Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
Phase 1Completed Nov 2014 Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants
Phase 1Completed 20 Sep 2016 A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
Phase 1Completed 9 Feb 2017 A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
Phase 1Completed 11 Apr 2019 A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants
Phase 1Completed 11 Nov 2021 A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 1Terminated 30 Sep 2022 A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 1Completed 10 Feb 2025 A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function
Phase 2Authorised not given "APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN".
Phase 3Authorised not given Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial
Phase 3Authorised not given Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial
Phase 3Authorised not given EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE)
Phase 3Authorised not given ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer
Phase 2Ended not given A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer
Phase 2Authorised not given A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
Phase 2Authorised not given A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy
Phase 3Authorised not given CARLHA-2_AN OPEN LABEL, RANDOMIZED, PHASE III STUDY EVALUATING THE EFFICACY OF ACOMBINATION OF APALUTAMIDE WITH RADIOTHERAPY AND LHRH AGONIST IN HIGH-RISK POST-PROSTATECTOMY BIOCHEMICALLY RELAPSED PROSTATE CANCER PATIENTS
Phase 2Authorised not given Surgical treatment with or without apalutamide in subjects with high risk prostate cancer who are candidates for radical prostatectomy and staged as oligometastatic with PSMA-PET (STAPLE)
Phase 2Authorised not given The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile
Phase 2Authorised not given AD ASTRA (Androgen Deprivation with Apalutamide and STereotactic RAdiotherapy)
Phase 3Authorised not given Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Apalutamide

Following is part of Solo: you see every change to Apalutamide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in